Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 11/20 | 0.59 |
| ▸ | CASP3 | P42574 | 9/20 | 0.53 |
| ▸ | CASP6 | P55212 | 7/20 | 0.53 |
| ▸ | CASP8 | Q14790 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473185 | 1.00 | CASP1 (0.59) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL6004074 | 1.00 | CASP1 (0.59) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL2003069 | 1.00 | CASP1 (0.59) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL473098 | 0.94 | CASP1 (0.61) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL2003509 | 0.94 | CASP1 (0.61) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL2003507 | 0.94 | CASP1 (0.61) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL473113 | 0.92 | CASP1 (0.59) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL473109 | 0.92 | CASP1 (0.59) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL473111 | 0.92 | CASP1 (0.59) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL6005359 | 0.91 | CASP1 (0.61) | CASP1CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960415-B2 | Caspase inhibitors and uses thereof | Vertex Pharmaceutical Incoporated (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090093416-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-09 | — | — | US | disclosed |
| EP-1631549-A2 | 3-[2-(3-AMINO-2-OXO-2H-PYRIDIN-1-YL)-ACETYLAMINO]-4-OXO-PENTANOIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004106304-A2 | 3 - [2- (3-AMINO-2-OXO-2H-PYRIDIN-1-YL) - ACETYLAMINO] - 4- OXO-PENTANOIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093416-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | CASP1 1/4885CASP3 3/4885CASP6 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.